Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002352
Status:
COMPLETED
Last Update Posted:
2007-10-02
First Post:
1999-11-02
Brief Title:
A Study of Lobucavir in Patients With AIDS
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Pilot Study of the Antiviral Activity of Multiple Doses of Oral Lobucavir in AIDS Patients
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if lobucavir is a safe and effective treatment for cytomegalovirus in patients with AIDS
Detailed Description:
Patients receive 1 of 2 doses of lobucavir for 28 days with 2 weeks of follow-up Weekly clinic visits are required
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AI459-007 | None | None | None |